Gain Therapeutics (GANX) Total Current Liabilities (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Total Current Liabilities of $3.9 million for Q1 2026, down 22.71% year-over-year from $5.0 million in Q1 2025, and up 15.93% quarter-over-quarter from $3.4 million in Q4 2025.
Gain Therapeutics (GANX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Gain Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 22.71% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 22.71% YoY), while the FY2025 annual figure was $3.4 million, down 14.29% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $3.9 million, up from $3.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $6.5 million in Q2 2024, with the low at $3.4 million in Q4 2025.
- The 5-year median for Total Current Liabilities is $4.6 million (2024), against an average of $4.7 million.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 81.24% in 2022, then decreased 22.71% in 2026.
- Gain Therapeutics' Total Current Liabilities stood at $4.1 million in 2022, then climbed by 19.99% to $4.9 million in 2023, then retreated by 20.98% to $3.9 million in 2024, then dropped by 14.29% to $3.4 million in 2025, then rose by 15.93% to $3.9 million in 2026.
- Business Quant data shows GANX's Total Current Liabilities at $3.9 million in Q1 2026, $3.4 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.43 Mn |
| Mar 31, 2026 | 3.89 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 5.03 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 6.52 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 4.95 Mn |
| Sep 30, 2023 | 5.76 Mn |
| Jun 30, 2023 | 5.59 Mn |
| Mar 31, 2023 | 5.15 Mn |
| Dec 31, 2022 | 4.13 Mn |
| Sep 30, 2022 | 4.33 Mn |
| Jun 30, 2022 | 3.41 Mn |
| Mar 31, 2022 | 4.22 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Sep 30, 2021 | 3.58 Mn |